Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis

San Diego, CA, December 4, 1998 -- Signal Pharmaceuticals today announced the successful completion of preclinical studies demonstrating the ability of two series of compounds to safely and effectively inhibit bone resorption in animal models of osteoporosis. The drug leads belong to a new class of small molecule compounds termed selective estrogen receptor modulators (SERMs), also referred to as 'designer estrogens.' SERMs are designed to mimic the positive effects of estrogen by inhibiting bone loss in postmenopausal women, while avoiding some of estrogen's adverse effects such as increased risk of breast and uterine cancer. Moreover, studies have demonstrated that some SERMs, such as Zeneca's tamoxifen (NolvadexTM) and Eli Lilly's raloxifene (EvistaTM), also have anti-estrogenic effects and therefore can be effective in preventing and treating breast cancer. Signal researchers are presenting data from successful preclinical studies at the joint meeting of The American Society for Bone and Mineral Research and The International Bone and Mineral Society being held in San Francisco, California, December 1-6.

Signal evaluated the efficacy of its novel SERMs in a rodent model of post-menopausal osteoporosis. Left untreated, these animals lose bone mass and eventually develop advanced stages of osteoporosis due to the loss of estrogen function. In the study, two series of drug leads were tested in parallel with estrogen and raloxifene for their ability to inhibit bone resorption. The study concluded that Signal's drug leads were twice as effective as raloxifene in preventing bone loss, at doses equal or less than raloxifene's therapeutic dose. In a separate study, these compounds also demonstrated superior safety, when compared with raloxifene, tamoxifen and estrogen, with regard to potential cancer risks in reproductive tissues. These drugs, if successfully developed, would provide clinicians with an alternative, non-estrogen treatment for osteoporosis

Contact: Neil Cohen
415-677-4455 x205
Noonan/Russo Communications

Page: 1 2 3 4

Related medicine news :

1. Signal identified that enables malarial parasites to target blood cells
2. Signaling pathway may be key to understanding roots of hypertension
3. Mouse study: Signal overload in Alzheimer brains
4. Neurobiologists Show How The Brain Processes Signals From Pheromones
5. Psychiatric Symptoms May Signal Brain Damage From Diet Pills
6. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
7. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
8. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
9. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
10. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
11. Pharmaceuticals and personal care products

Post Your Comments:

(Date:12/5/2018)... ... December 05, 2018 , ... Marking its seventh year, Pacifica ... “A Toast Heard ‘Round the World” on New Year’s Eve. Each year event ... community (alumni, students, faculty members, staff, families, and friends of the institution) to join ...
(Date:12/5/2018)... , ... December 05, 2018 , ... Northcentral University (NCU) ... of nursing. Available starting today and on a weekly rolling basis to registered nurses, ... Nursing Practice in Executive Leadership (DNP) will prepare degree candidates to become leaders ...
(Date:12/5/2018)... ... December 05, 2018 , ... To change the ... transformative conference at the DoubleTree Hilton Hotel in Newark, California. Led by world-renowned ... Founder/Director of Watson Caring Science Institute, participants and esteemed guests discussed the impact ...
(Date:11/29/2018)... ... ... “The total demand for technologies used in drug discovery reached approximately $4.9 billion ... project the market will grow at a healthy annual rate of 6.4% over the ... ages.” , This report details market activity in the areas of chromatography, sequencing, liquid ...
(Date:11/28/2018)... ... November 28, 2018 , ... CBD merchants throughout the United ... available. Previously, merchants were unable to obtain legitimate CBD processing accounts without being ... down their business after being put on the Visa and Mastercard processing blacklist. ...
Breaking Medicine News(10 mins):
(Date:11/28/2018)... CITY (PRWEB) , ... November 28, 2018 , ... nJoy ... high levels of myopia and astigmatism in one easy procedure following FDA approval of ... the Toric ICL, is scheduled at nJoy Vision OKC on November 29th by Edward ...
(Date:11/28/2018)... ATLANTA (PRWEB) , ... November 28, 2018 , ... ... to announce board certified reproductive endocrinologist Monica Best, M.D. has joined ... Mark Perloe, Desireé McCarthy-Keith, Anne Namnoum, and their most recent addition, Natalie Stentz. ...
(Date:11/28/2018)... ... November 28, 2018 , ... On ... Alliance of Pennsylvania, Ohio, and West Virginia (SimPOW) at their corporate headquarters in ... Suzan Kardong-Edgren and Dana Bargerstock were recognized in the opening session. Attendees enjoyed ...
Breaking Medicine Technology:
Cached News: